Showing results (21-30 of 79) with videos related to
Sort By:
Pageof 8
Expert Review of Anticancer Therapy|October 16, 2004
Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomitingRudolph M NavariExpert Review of Anticancer Therapy|November 6, 2008
Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingRudolph M NavariFuture Oncology (London, England)|October 12, 2018
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxisRudolph M NavariExpert Review of Anticancer Therapy|September 15, 2015
Rolapitant for the treatment of chemotherapy-induced nausea and vomitingRudolph M NavariExpert Opinion on Investigational Drugs|November 29, 2007
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingRudolph M NavariDrugs|February 14, 2013
Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agentsRudolph M NavariExpert Opinion on Drug Safety|November 12, 2019
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective reviewRudolph M NavariDrugs|April 17, 2009
Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developmentsRudolph M NavariCancer Medicine|March 27, 2025
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical TrialRudolph M Navari, Erminio BonizzoniThe Annals of Pharmacotherapy|August 19, 2003
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonistsRudolph M Navari, Jim M KoellerPageof 8